BioAtla (NASDAQ:BCAB) Posts Quarterly Earnings Results, Beats Estimates By $0.20 EPS

BioAtla (NASDAQ:BCAB) issued its earnings results on Tuesday. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.20, FiscalAI reports. The firm had revenue of $2.00 million during the quarter, compared to analyst estimates of $0.70 million.

BioAtla Stock Up 4.5%

Shares of BCAB stock traded up $0.01 on Tuesday, reaching $0.16. The company had a trading volume of 1,165,021 shares, compared to its average volume of 1,276,868. The stock has a market capitalization of $10.22 million, a PE ratio of -0.14 and a beta of 1.08. BioAtla has a one year low of $0.13 and a one year high of $1.43. The business’s 50-day moving average is $0.20 and its 200 day moving average is $0.53.

Institutional Investors Weigh In On BioAtla

Several hedge funds and other institutional investors have recently made changes to their positions in BCAB. Marshall Wace LLP bought a new position in BioAtla in the 4th quarter valued at approximately $508,000. Woodline Partners LP bought a new stake in shares of BioAtla during the first quarter worth $26,000. Susquehanna International Group LLP grew its stake in shares of BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after buying an additional 177,760 shares during the last quarter. Millennium Management LLC acquired a new position in shares of BioAtla during the third quarter worth $235,000. Finally, Vanguard Group Inc. increased its holdings in shares of BioAtla by 9.1% during the third quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock worth $1,339,000 after buying an additional 162,647 shares in the last quarter. 77.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently issued reports on BCAB. Weiss Ratings reissued a “sell (d-)” rating on shares of BioAtla in a research note on Friday, January 9th. Rodman & Renshaw began coverage on BioAtla in a research note on Tuesday, January 13th. They set a “buy” rating and a $4.00 target price for the company. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $4.00.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.